UBE2E1 (UbcH6) [6His-tagged]

Ubiquigent

Catalog No: UBI-62-0075-020

Click here to view the Ubiquigent^TM Product Dashboard and hundreds of great reagents for ubiquitin-proteasome-related research.

Customer Notice Regarding Orders for Ubiquigent Products: From September 2020, orders for Ubiquigent products must total at least $700 to enable prompt delivery. Orders less than this amount may be subject to unpredictable wait times. Please contact us for further details.

Species Reactivity: Human  
Source: E. coli expression  
Formula: 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol  
Concentration: 1 mg/ml  
Molecular Weight: ~26 kDa  
Protein Sequence: Accession number: AAH09139. For full protein sequence information download the Certificate of Analysis pdf.  
Quality Control Protein Identification: Confirmed by mass spectrometry.  
Quality Control Activity: E2-Ubiquitin Thioester Loading Assay: The activity of His-UBE2E1 was validated by loading E1 UBE1 activated ubiquitin onto the active cysteine of the His-UBE2E1 E2 enzyme via a transthiolation reaction. Incubation of the UBE1 and His-UBE2E1 enzymes in the presence of ubiquitin and ATP at 30 °C was compared at two time points, T0 and T10 minutes. Sensitivity of the ubiquitin/His-UBE2E1 thioester bond to the reducing agent DTT was confirmed.   

Background

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including regulated and targeted proteasomal degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). UBE2E1 is a member of the E2 ubiquitin-conjugating enzyme family and cloning of the human gene was first described by Nuber et al. (1996). UBE2E1 shares 74% sequence homology with UBE2D1 and contains an N-terminal extension of approximately 40 amino acids. A tumour suppressor candidate, tumour-suppressing subchromosomal transferable fragment cDNA (TSSC5) is located in the region of human chromosome 11p15.5 linked with Beckwith-Wiedemann syndrome and associated with susceptibility to Wilms tumor (Yamada and Gorbsky. 2006). UBE2E1 functions in concert with a novel ubiquitin ligase RING-finger protein 105 (RING105) to ubiquitylate TSSC5. Regulation of TSSC5 function mediated via UBE2E1 and RING105 could define a novel ubiquitin proteasome pathway. The E3 ligase Ro52 mediates ubiquitylation of its substrates through UBE2E1 in the nucleus and translocation of this E3 ligase to the nucleus is dependent on amino acids 381-470 of the B30.2 region (Espinosa et al., 2008). UBE2E1 also modulates the transcriptional repression activity of Ataxin-1, the gene product of Spinocerebellar ataxia type 1 (SCA1). SCA1 is an autosomal-dominant neurodegenerative disorder characterized by ataxia and progressive motor deterioration, which is caused by expansion of the polyglutamine tract in Ataxin-1. Ataxin-1 binds with UBE2E1 through its AXH domain and in vitro the rate of Ataxin-1 degradation is regulated by UBE2E1. UBE2E1 may have some therapeutic potential in the treatment of SCA1 by modulating the degradation of Ataxin-1 (Hong et al., 2008; Lee et al., 2008).

References:

Espinosa A, Oke V, Elfving A, Nyberg F, Covacu R, Wahren-Herlenius M (2008) The autoantigen Ro52 is an E3 ligase resident in the cytoplasm but enters the nucleus upon cellular exposure to nitric oxide. Exp Cell Res 314, 3605-13.

Hong S, Lee S, Cho SG, Kang S (2008) UbcH6 interacts with and ubiquitinates the SCA1 gene product ataxin-1. Biochem Biophys Res Commun 371, 256-60.

Lee S, Hong S, Kang S (2008) The ubiquitin-conjugating enzyme UbcH6 regulates the transcriptional repression activity of the SCA1 gene product ataxin-1. Biochem Biophys Res Commun 372, 735-40.

Nuber U, Schwarz S, Kaiser P, Schneider R, Scheffner M (1996) Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5. J Biol Chem 271, 2795-800.

Yamada HY, Gorbsky GJ (2006) Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105. Oncogene 25, 1330-9.